<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380118</url>
  </required_header>
  <id_info>
    <org_study_id>PR/CT 0309/2014 (SC)</org_study_id>
    <secondary_id>HKU 789813M</secondary_id>
    <nct_id>NCT02380118</nct_id>
  </id_info>
  <brief_title>IM Olanzapine Versus Haloperidol or Midazolam</brief_title>
  <official_title>Intramuscular Olanzapine Versus Haloperidol or Midazolam for the Management of Acute Agitation in the Emergency Department - a Multicentre Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Mary Hospital, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tuen Mun Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pamela Youde Nethersole Eastern Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruttonjee Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prince of Wales Hospital, Shatin, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IM olanzapine is safer (fewer adverse
      events) and more effective (shorter time to sedation) than conventional haloperidol or
      midazolam when used in the management of acute agitation in the emergency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address significant knowledge gaps by several means:

        1. Investigate IM use of sedating drugs within a predominantly Chinese population, to
           address this void in international literature impacting the management of acute
           agitation.

           The multi-centre RCT will determine the safety and efficacy of IM olanzapine, in
           comparison with conventional medicines (haloperidol or midazolam) in a three-arm
           comparison for the sedation of acutely agitated patients in AEDs. Specifically, we aim
           to determine if administration of IM olanzapine (a)is more effective than sedation with
           IM haloperidol or IM midazolam alone; (b)is safer than sedation with comparison arms;
           (c)decreases the amount of subsequent redosing or alternative drugs required; (d)is more
           favourable than the haloperidol and midazolam arms with respect to safety, efficacy and
           adverse events.

        2. Investigate potential variables leading to AED attendance and/or admission requiring
           parenteral sedation. These may include patient demographic and regular medications and
           adherence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to achieve adequate sedation</measure>
    <time_frame>Within 60 minutes from drug administration</time_frame>
    <description>Adequate sedation is determined by a 6-point validated scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total study drug doses administered; alternative drugs and doses used</measure>
    <time_frame>From Accident &amp; Emergency Department(AED) admission to transfer or discharge from AED, an expected average of 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval</measure>
    <time_frame>From Accident &amp; Emergency Department(AED) admission to transfer or discharge from AED, an expected average of 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AED length of stay (LOS)</measure>
    <time_frame>From Accident &amp; Emergency Department(AED) admission to transfer or discharge from AED, an expected average of 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From Accident &amp; Emergency Department(AED) admission to transfer or discharge from AED, an expected average of 1 hour</time_frame>
    <description>including airway management (jaw thrust, oral, nasal airway), need for assisted ventilation (bag/mask, intubation), oxygen desaturation &lt;90%, systolic BP&lt;90 mmHg, dystonic reactions, seizures, vomiting or aspiration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Acute Agitation, Behavioural Emergency</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>ZYPREXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Haloperidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Accident &amp; Emergency Department patients, requiring parenteral drug sedation (as
             determined by an emergency clinician) will be enrolled.

        Exclusion Criteria:

          -  Patients will be excluded if there are

               1. known hypersensitivity or contraindication to the study drugs

               2. reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia)

               3. known pregnancy

               4. acute alcohol withdrawal

               5. patients aged&gt;75 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther WY Chan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther WY Chan, PhD</last_name>
    <phone>852 6716 0700</phone>
    <email>ewchan@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shijian Lao, Bsc</last_name>
    <phone>852 2831 5118</phone>
    <email>kiml1@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antony CP Wong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin A. Graham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Pong Leung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruttonjee Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tong Shun Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Tat Lui</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>United Christian Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiu Fung Lam</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Knott JC, Bennett D, Rawet J, Taylor DM. Epidemiology of unarmed threats in the emergency department. Emerg Med Australas. 2005 Aug;17(4):351-8.</citation>
    <PMID>16091097</PMID>
  </reference>
  <reference>
    <citation>Chan EW, Taylor DM, Knott JC, Phillips GA, Castle DJ, Kong DC. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med. 2013 Jan;61(1):72-81. doi: 10.1016/j.annemergmed.2012.07.118. Epub 2012 Sep 13.</citation>
    <PMID>22981685</PMID>
  </reference>
  <reference>
    <citation>Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med. 2006 Jan;47(1):61-7. Epub 2005 Aug 18.</citation>
    <PMID>16387219</PMID>
  </reference>
  <reference>
    <citation>Chan EW, Taylor DM, Knott JC, Kong DC. Variation in the management of hypothetical cases of acute agitation in Australasian emergency departments. Emerg Med Australas. 2011 Feb;23(1):23-32. doi: 10.1111/j.1742-6723.2010.01348.x. Epub 2010 Nov 22.</citation>
    <PMID>21091874</PMID>
  </reference>
  <reference>
    <citation>Chan EW, Knott JC, Taylor DM, Phillips GA, Kong DC. Intravenous olanzapine--another option for the acutely agitated patient? Emerg Med Australas. 2009 Jun;21(3):241-2. doi: 10.1111/j.1742-6723.2009.01190.x.</citation>
    <PMID>19527287</PMID>
  </reference>
  <reference>
    <citation>Chan EW, Taylor DM, Knott JC, Liew D, Kong DC. The pharmacoeconomics of managing acute agitation in the emergency department: what do we know and how do we approach it? Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):589-95. doi: 10.1586/erp.12.53. Review.</citation>
    <PMID>23186399</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Esther Wai Yin Chan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>emergency</keyword>
  <keyword>emergency medicine</keyword>
  <keyword>sedation</keyword>
  <keyword>acute agitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

